CAMBRIDGE, Mass.--(BUSINESS WIRE)--Targanta Therapeutics Corporation (Nasdaq: TARG), today announced the appointment of Stéphane Bancel and Rosemary A. Crane to its Board of Directors, effective immediately. The newly appointed directors add deep operational and commercial expertise to the Board as Targanta continues to build its infrastructure in support of the potential commercial launch of its lead antibiotic drug candidate, oritavancin.
